|Dr. Waleed H. Hassanein||Founder, MD, CEO, Pres & Director||939.73k||N/A||1968|
|Mr. Stephen Gordon||CFO. Treasurer & Sec.||512.34k||N/A||1968|
|Dr. Tamer I. Khayal||Chief Commercial Officer||533.69k||N/A||1969|
|Mr. John F. Carey||VP of Operations||N/A||N/A||1965|
|Mr. Ike Okonkwo||VP of Fin. & Accounting||N/A||N/A||1971|
|Mr. Mark Anderson||Sr. Director of Technology Devel.||N/A||N/A||N/A|
|Ms. Susan Goodman||VP of HR||N/A||N/A||N/A|
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 3; Compensation: 7.